×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

NOVARTIS LAUNCHES REVIEW FOR NEW ARTHRITIS DRUG

Five Shops Seek Direct-to-Consumer Account

Published on .

NEW YORK (AdAge.com) -- Novartis, East Hanover, N.J., has launched a review to handle the direct-to-consumer account for its Cox-2 arthritis drug in development (known as Cox-189) and scheduled for a 2003 launch, people familiar with the matter said.

Shops involved are Cline, Davis Mann, New York Abelson-Taylor, Chicago; WPP Group's Ogilvy Mather, New York and Omnicom Group's Merkley Newman Harty, New York, the people said.

Novartis declined to comment.

Professional-marketing shop Abelson is expected to find a consumer agency to partner with. CDM may handle both areas, while the other two shops are expected to find professional shops to join with in the pitch.

The drug is expected to be the fifth Cox-2 on the market following two each by Pfizer/Pharmacia and Merck.

Most Popular